#United States #Cambridge #ALS #NeuroSense #PrimeC

NeuroSense Joins Roth Webinar on ALS Treatment

On July 8, 2026, NeuroSense Therapeutics Ltd., a company focused on developing groundbreaking treatments for neurodegenerative diseases, will participate in a significant webinar organized by Roth Capital Partners. Titled "A Quest to Outrun Amyotrophic Lateral Sclerosis (ALS)," this event aims to tackle critical issues surrounding the current approaches to ALS treatment, addressing the persistent gaps in therapy and emerging innovations that could potentially alter the disease's trajectory.

Key Experts and Discussion Points

The live webinar will begin at 11:00 a.m. Eastern Time and will be moderated by Dr. Boobalan Pachaiyappan, a Managing Director at Roth, who specializes in the biotechnology sector. Attendees can expect to hear insights from Professor Jeremy Shefner, Chair of Neurology at the Barrow Neurological Institute and co-founder of the Northeast ALS Consortium (NEALS). Alon Ben-Noon, Chief Executive Officer of NeuroSense, will also contribute to the conversation, providing a comprehensive view of the developments in ALS therapies.

The discussion is set to cover various pressing topics in ALS drug development, including the persistent medical needs that patients face. One of the main subjects will be the clinical trial endpoints, which are critical for accurately capturing the progression of ALS. NeuroSense’s lead product candidate, PrimeC, will be spotlighted, showcasing its unique mechanistic and clinical positioning compared to existing treatments. The webinar will touch upon the pivotal Phase 3 PARAGON study and its objectives as NeuroSense seeks potential FDA accelerated approval.

About NeuroSense Therapeutics

NeuroSense is on the frontier of biotech innovation, particularly in the realm of severe neurodegenerative diseases like ALS and Alzheimer's disease. Their flagship product, PrimeC, represents a novel oral therapy that targets multiple biological pathways linked to disease advancement. These include inflammation within the nervous system, oxidative stress, and the role of iron metabolism—all essential factors in neurodegeneration.

Promising data from NeuroSense’s Phase 2b PARADIGM study highlighted its efficacy in slowing down ALS progression significantly. This study also revealed crucial biological activity related to ALS through various biomarkers, demonstrating PrimeC's multi-target mechanism of action. Notably, long-term data suggests a meaningful survival advantage, turning PrimeC into a beacon of hope for ALS treatment.

The company has received FDA clearance to commence a pivotal Phase 3 trial (PARAGON) with around 300 participants expected to enroll, mainly from the United States. This represents a vital step towards a deeper understanding of ALS treatment and how new therapies can be integrated into clinical practice.

Insights on PrimeC

PrimeC is an extended-release oral formulation created through a unique combination of two already approved drugs, ciprofloxacin and celecoxib. It is designed to synergistically target several mechanisms implicated in both ALS and Alzheimer's Disease, such as neuronal degeneration, inflammation, iron accumulation, and faulty RNA regulation. By addressing these multifaceted issues, PrimeC aims to slow down the progression of these debilitating conditions.

Understanding ALS

Amyotrophic lateral sclerosis (ALS) remains a challenging, incurable neurodegenerative disease leading to complete paralysis and fatality usually between 2 to 5 years post-diagnosis. Each year, more than 5,000 individuals receive an ALS diagnosis in the United States, highlighting the urgent need for effective therapies as the number of cases is projected to rise significantly by 2040.

As NeuroSense engages in this pivotal discussion, expectations are high for innovative solutions to emerge from the ongoing research and trials. This webinar promises to shed light on not just the current landscape of ALS treatment, but also future possibilities that could redefine patient care in this challenging field.

To join this insightful discussion, interested individuals can register in advance for the webinar, marking a significant opportunity for learning about the future of ALS treatment directly from industry leaders. Stay updated with NeuroSense Therapeutics by visiting their website and following their progress on various social media platforms.